Good evening :)
Place Order
Add to Watchlist

Torrent Pharmaceuticals Ltd

TORNTPHARM

Torrent Pharmaceuticals Ltd

TORNTPHARM
Health CarePharmaceuticals
LargecapWith a market cap of ₹1,04,733 cr, stock is ranked 83
Low RiskStock is 1.76x as volatile as Nifty
3,101.950.23% (+7.10)
3,101.950.23% (+7.10)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
LargecapWith a market cap of ₹1,04,733 cr, stock is ranked 83
Low RiskStock is 1.76x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹1,04,733 cr, stock is ranked 83
Low RiskStock is 1.76x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
58.1215.280.90%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.706.300.53%

Forecast & Ratings

Detailed Forecast 
74%
Analysts have suggested that investors can buy this stock

from 27 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Torrent Pharmaceuticals Limited is engaged in the manufacture and sale of branded, as well as unbranded generic pharmaceutical products.

Investor Presentation

View older 

Oct 25, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 7.06%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 3.52% to 2.88%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 30.58%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue6,912.506,038.996,248.677,729.858,060.618,061.488,704.609,665.2910,874.1311,319.00
Raw Materialssubtract1,725.041,931.392,035.672,136.252,300.052,425.662,368.152,569.002,841.227,630.00
Power & Fuel Costsubtract92.59107.98118.77132.46128.19122.94144.19155.28145.20
Employee Costsubtract842.35993.411,135.251,403.791,429.041,439.621,526.451,677.691,984.40
Selling & Administrative Expensessubtract847.92964.141,084.651,299.491,317.151,155.101,278.571,502.701,674.65
Operating & Other expensessubtract639.63441.50226.241,074.76594.52381.171,244.11873.43714.72
Depreciation/Amortizationsubtract237.55306.92408.60617.69654.38657.79662.16706.59808.27811.00
Interest & Other Itemssubtract183.98205.56308.48503.75450.71352.94255.06333.44353.56299.00
Taxes & Other Itemssubtract610.20154.54252.90125.38161.85274.38448.73601.93695.73777.00
EPS51.2127.5820.0312.8930.2836.9922.9636.7948.9453.24
DPS17.507.007.008.5016.0017.5024.0022.0028.0028.00
Payout ratio0.340.250.350.660.530.471.050.600.570.53

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 25PDF
Jan 25PDF
Oct 26PDF
FY 2023

Annual report

PDF

Investor Presentation

May 30PDF
Jan 25PDF
Oct 21PDF
+2 more
FY 2024

Annual report

PDF

Investor Presentation

Aug 7PDF
FY 2025

Annual Report Pending

Investor Presentation

Oct 25PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Torrent Pharmaceuticals Ltd63.2315.280.90%
Sun Pharmaceutical Industries Ltd44.526.350.76%
Cipla Ltd28.834.430.88%
Mankind Pharma Ltd53.9210.77

Price Comparison

Compare TORNTPHARM with any stock or ETF
Compare TORNTPHARM with any stock or ETF
TORNTPHARM
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding71.25%3.69%3.39%14.46%7.21%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep12.84%13.15%14.09%14.14%14.22%14.46%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Torrent Pharmaceuticals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Kotak Emerging Equity Fund - Growth - Direct Plan

Growth
0.4832%1.00%-0.22%25/75 (-3)
UTI Flexi Cap Fund - Growth - Direct Plan

Growth
0.2897%1.10%-0.11%19/70 (0)
Nippon India Large Cap Fund - Growth - Direct Plan

Growth
0.1865%0.57%0.57%43/76 (+28)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

TORNTPHARM has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.90%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹9.05 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJun 21, 2024

Final
Final | Div/Share: ₹6.00

Dividend/Share

6.00

Ex DateEx Date

Jun 21, 2024

Cash Dividend

Ex DateEx DateFeb 12, 2024

Interim
Interim | Div/Share: ₹22.00

Dividend/Share

22.00

Ex DateEx Date

Feb 12, 2024

Cash Dividend

Ex DateEx DateJun 23, 2023

Final
Final | Div/Share: ₹8.00

Dividend/Share

8.00

Ex DateEx Date

Jun 23, 2023

Cash Dividend

Ex DateEx DateFeb 3, 2023

Interim
Interim | Div/Share: ₹14.00

Dividend/Share

14.00

Ex DateEx Date

Feb 3, 2023

Cash Dividend

Ex DateEx DateJun 3, 2022

Special
Special | Div/Share: ₹15.00

Dividend/Share

15.00

Ex DateEx Date

Jun 3, 2022

News & Opinions
Spotlight
Volumes spurt at Torrent Pharmaceuticals Ltd counter

Capri Global Capital Ltd, Marico Ltd, Honeywell Automation India Ltd, Laxmi Organic Industries Ltd are among the other stocks to see a surge in volumes on BSE today, 30 October 2024.Torrent Pharmaceuticals Ltd registered volume of 106.33 lakh shares by 10:47 IST on BSE, a 2179.99 fold spurt over two-week average daily volume of 4878 shares. The stock slipped 2.38% to Rs.3,134.50. Volumes stood at 7419 shares in the last session.Capri Global Capital Ltd clocked volume of 3.17 lakh shares by 10:47 IST on BSE, a 34.85 times surge over two-week average daily volume of 9093 shares. The stock gained 13.53% to Rs.209.80. Volumes stood at 5128 shares in the last session.Marico Ltd recorded volume of 1.91 lakh shares by 10:47 IST on BSE, a 9.7 times surge over two-week average daily volume of 19653 shares. The stock gained 3.87% to Rs.653.15. Volumes stood at 26022 shares in the last session.Honeywell Automation India Ltd witnessed volume of 744 shares by 10:47 IST on BSE, a 4.3 times surge over two-week average daily volume of 173 shares. The stock dropped 7.54% to Rs.45,297.20. Volumes stood at 128 shares in the last session.Laxmi Organic Industries Ltd saw volume of 2.9 lakh shares by 10:47 IST on BSE, a 4.05 fold spurt over two-week average daily volume of 71540 shares. The stock increased 8.61% to Rs.274.35. Volumes stood at 83736 shares in the last session.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
Torrent Pharma Q2 PAT climbs 17% YoY to Rs 453 crore

Revenue from operations rose 8.60% year on year (YoY) to Rs 2,889 crore in the quarter ended 30 September 2024. Profit before tax stood at Rs 661 crore in September 2024 quarter, up 18.24% from Rs 559 crore posted in same quarter last year. Operating EBITDA stood at Rs 939 crore in Q2 FY25, registering a growth of 13.81% as against Rs 825 crore reported in Q2 FY24. The company's India revenue grew by 13% YoY to Rs 1,632 crore in Q2 FY25, led by outperformance in focus therapies. As per All India Organization of Chemists & Druggists (AIOCD) secondary market data, IPM growth for the quarter was 8%. Torrent's chronic business grew at 14% versus IPM growth of 9%, driven by strong revival in cardiac divisions and continued traction in anti-diabetes (OAD) new launches. Torrent Pharma's Brazil revenue rose by 4% to Rs 263 crore and on constant currency terms revenues was up by 17% at R$ 174 million. As per IQVIA, market growth for the quarter was 8%. Growth was aided by performance of top brands, new launches and growth in generic segment. The Germany revenue stood at Rs 288 crore, by 8%. Constant currency revenue at Euro 31 million was up by 6%. Growth momentum continues with incremental tender wins since last five quarters. The company's US revenue stood at Rs 268 crore in Q2 FY25, up by 8%. Constant currency revenue was at $32 million, up by 7% YoY. Sequential quarter sales were at a similar level. Torrent Pharmaceuticals is the flagship company of the Torrent Group. It is ranked 6th in the Indian Pharmaceuticals Market and is amongst the top five in the therapeutics segments of cardiovascular (CV), gastro intestinal (GI), central nervous system (CNS), vitamins minerals nutritional (VMN) and cosmo-dermatology. Shares of Torrent Pharmaceuticals rallied 3.63% to end at Rs 3,436.65 on the BSE.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Torrent Pharmaceuticals consolidated net profit rises 17.36% in the September 2024 quarter

Net profit of Torrent Pharmaceuticals rose 17.36% to Rs 453.00 crore in the quarter ended September 2024 as against Rs 386.00 crore during the previous quarter ended September 2023. Sales rose 7.72% to Rs 2831.00 crore in the quarter ended September 2024 as against Rs 2628.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2831.002628.00 8 OPM %33.1731.39 - PBDT859.00760.00 13 PBT661.00559.00 18 NP453.00386.00 17 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Torrent Pharmaceuticals announces board meeting date

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Torrent Pharmaceuticals announces change in senior management

Torrent Pharmaceuticals announced that Pranav Mehta has been elevated as Executive Director from Vice President of the company with effect from 01 April 2024. Powered by Capital Market - Live

3 months agoCapital Market - Live

Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%

3 months agoBusiness Standard

Torrent Pharmaceuticals set to acquire KKR’s stake in JB Chemicals

3 months agoThe Hindu Businessline

Torrent Pharma Q1 Results Review- Segment Continues To Drive Growth: Centrum

3 months agoBloomberg Quint

Stocks in news: HUL, Vedanta, DRL, L&T, Axis Bank, Torrent Pharma and Titagarh Rail

3 months agoBusiness Today

Torrent Pharma tanks 4% post Q1FY25 results; analysts update target prices

3 months agoBusiness Standard